目的:为探究外周血Zonulin在评估系统性红斑狼疮(SLE)患者肠道通透性、疾病活动度以及受累脏器的临床价值。方法:共纳入60名SLE女性患者,通过ELISA测量血清连蛋白(Zonulin)及脂肪酸结合蛋白(IFABP)水平,并收集系统性红斑狼疮疾病活动指...目的:为探究外周血Zonulin在评估系统性红斑狼疮(SLE)患者肠道通透性、疾病活动度以及受累脏器的临床价值。方法:共纳入60名SLE女性患者,通过ELISA测量血清连蛋白(Zonulin)及脂肪酸结合蛋白(IFABP)水平,并收集系统性红斑狼疮疾病活动指数(SLEDAI-2k)评分及临床指标评估疾病活动度,通过线性回归和Pearson相关性评估外周血Zonulin、IFABP水平与SLEDAI-2k及临床指标之间的相关性。结果:SLE患者中外周血Zonulin (p p p p 2 = 0.5247, p p p Objective: To explore the clinical value of peripheral blood Zonulin in the evaluation of intestinal permeability, disease activity, and affected organs in patients with systemic lupus erythematosus (SLE). Methods: 60 female patients with SLE were enrolled. Serum levels of Zonulin and intestinal fatty acid-binding protein (IFABP) were measured by ELISA. The SLE Disease Activity Index (SLEDAI-2k) score and clinical indicators were collected to assess disease activity. Linear regression and Pearson correlation were used to evaluate the correlations between Zonulin, IFABP in peripheral blood and SLEDAI-2k, clinical indicators. Results: Compared to healthy controls, the levels of Zonulin (p p p p 2 = 0.5247, p p p < 0.001) was negatively correlated. However, there was no statistically significant difference in Zonulin and IFABP levels in peripheral blood among patients with different organ involvements. Conclusion: Zonulin in peripheral blood may be associated with disease activity and exacerbation, potentially serving as a biomarker for the severity and progression of SLE, but it is unrelated to the involved organs and systems.展开更多
文摘目的:为探究外周血Zonulin在评估系统性红斑狼疮(SLE)患者肠道通透性、疾病活动度以及受累脏器的临床价值。方法:共纳入60名SLE女性患者,通过ELISA测量血清连蛋白(Zonulin)及脂肪酸结合蛋白(IFABP)水平,并收集系统性红斑狼疮疾病活动指数(SLEDAI-2k)评分及临床指标评估疾病活动度,通过线性回归和Pearson相关性评估外周血Zonulin、IFABP水平与SLEDAI-2k及临床指标之间的相关性。结果:SLE患者中外周血Zonulin (p p p p 2 = 0.5247, p p p Objective: To explore the clinical value of peripheral blood Zonulin in the evaluation of intestinal permeability, disease activity, and affected organs in patients with systemic lupus erythematosus (SLE). Methods: 60 female patients with SLE were enrolled. Serum levels of Zonulin and intestinal fatty acid-binding protein (IFABP) were measured by ELISA. The SLE Disease Activity Index (SLEDAI-2k) score and clinical indicators were collected to assess disease activity. Linear regression and Pearson correlation were used to evaluate the correlations between Zonulin, IFABP in peripheral blood and SLEDAI-2k, clinical indicators. Results: Compared to healthy controls, the levels of Zonulin (p p p p 2 = 0.5247, p p p < 0.001) was negatively correlated. However, there was no statistically significant difference in Zonulin and IFABP levels in peripheral blood among patients with different organ involvements. Conclusion: Zonulin in peripheral blood may be associated with disease activity and exacerbation, potentially serving as a biomarker for the severity and progression of SLE, but it is unrelated to the involved organs and systems.
